Enliven Therapeutics, Inc. announced that it has entered into a securities purchase agreement to issue 5,357,144 shares at a price of $14 per share for the gross proceeds of $75,000,016 and pre funded warrants at a price of $13.999 per warrant for the total gross proceeds of $90,000,000 on March 19, 2024. The Pre-Funded Warrants will be exercisable into 1,071,505 shares and will have an exercise price of $0.001 per share of common stock.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
23.78 USD | -2.92% | +12.96% | +71.32% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+71.32% | 1.15B | |
+2.74% | 108B | |
+10.08% | 105B | |
+1.57% | 23.46B | |
-11.89% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.95% | 17.19B | |
+5.98% | 13.99B | |
+36.10% | 12.53B |
- Stock Market
- Equities
- ELVN Stock
- News Enliven Therapeutics, Inc.
- Enliven Therapeutics, Inc. announced that it expects to receive $90.000014 million in funding